Dual loss of the SWI/SNF complex ATPases SMARCA4/BRG1 and SMARCA2/BRM is highly sensitive and specific for small cell carcinoma of the ovary, hypercalcaemic type.
about
Genomic/Epigenomic Alterations in Ovarian Carcinoma: Translational Insight into Clinical PracticeSMARCA4-inactivating mutations increase sensitivity to Aurora kinase A inhibitor VX-680 in non-small cell lung cancersThe disparate origins of ovarian cancers: pathogenesis and prevention strategies.SMARCB1 (INI-1)-deficient Sinonasal Carcinoma: A Series of 39 Cases Expanding the Morphologic and Clinicopathologic Spectrum of a Recently Described Entity.BRG1 promotes hepatocarcinogenesis by regulating proliferation and invasivenessIntratumoral heterogeneity analysis reveals hidden associations between protein expression losses and patient survival in clear cell renal cell carcinoma.Immunohistochemistry Successfully Uncovers Intratumoral Heterogeneity and Widespread Co-Losses of Chromatin Regulators in Clear Cell Renal Cell Carcinoma.Molecular analyses reveal close similarities between small cell carcinoma of the ovary, hypercalcemic type and atypical teratoid/rhabdoid tumor.The histone methyltransferase EZH2 is a therapeutic target in small cell carcinoma of the ovary, hypercalcaemic type.SMARCA4-deficient pulmonary adenocarcinoma: clinicopathological, immunohistochemical, and molecular characteristics of a novel aggressive neoplasm with a consistent TTF1(neg)/CK7(pos)/HepPar-1(pos) immunophenotype.Recurrent IDH2 R172X mutations in sinonasal undifferentiated carcinoma.The changing landscape of gynaecological cancer diagnosis: implications for histopathological practice in the 21st century.Mammalian SWI/SNF complexes in cancer: emerging therapeutic opportunities.Widespread Post-transcriptional Attenuation of Genomic Copy-Number Variation in Cancer.SMARCA4-Deficient Carcinoma of Unknown Primary Presenting with Fatal Paraneoplastic Hypercalcemia in a Heart Transplant Recipient: First Report in a Male Patient.PRC2-mediated repression of SMARCA2 predicts EZH2 inhibitor activity in SWI/SNF mutant tumors.Ovarian Cancers: Genetic Abnormalities, Tumor Heterogeneity and Progression, Clonal Evolution and Cancer Stem Cells.Dominant-negative SMARCA4 mutants alter the accessibility landscape of tissue-unrestricted enhancers.High expression of SMARCA4 or SMARCA2 is frequently associated with an opposite prognosis in cancer.Immune-Active Microenvironment in Small Cell Carcinoma of the Ovary, Hypercalcemic Type: Rationale for Immune Checkpoint Blockade.Loss of SMARCA4 (BRG1) protein expression as determined by immunohistochemistry in small-cell carcinoma of the ovary, hypercalcaemic type distinguishes these tumours from their mimics.Lifting Up the HAT: Synthetic Lethal Screening Reveals a Novel Vulnerability at the CBP-p300 Axis.The BRG1 ATPase of human SWI/SNF chromatin remodeling enzymes as a driver of cancer.Claudin-4 expression distinguishes SWI/SNF complex-deficient undifferentiated carcinomas from sarcomas.Concurrent ARID1A and ARID1B inactivation in endometrial and ovarian dedifferentiated carcinomas.Loss of expression of the SWI/SNF complex is a frequent event in undifferentiated/dedifferentiated urothelial carcinoma of the urinary tract.
P2860
Q26740622-533B028E-597B-4660-9CC3-422512AD5CD8Q28818608-AF6EF138-7256-449E-A72E-2DBBA43B4E77Q30240709-7AD98260-7CC8-4607-9475-F27D61577768Q30252961-CB251793-AEA1-4822-B3B5-A83DC7F20A32Q33898452-FC641C1A-8D3F-4DA7-B4E8-177E13801FA4Q33913967-BCB3FDBA-EC66-455B-B2B8-606EF8753CFFQ36169098-FA47DAF6-9791-4EDD-B95C-A12A13ED3419Q36738953-22380B84-DD04-4758-89A7-D2E7E3FD5345Q38706007-AAF1FFA5-14C3-4210-A0D5-73CA243B60D4Q38757918-4C0862EF-88B0-4F21-8F8E-BC9D54699F3CQ39022637-1806C331-446C-46F5-A03F-C695209456BEQ39037647-5EAC75B9-73C6-4544-A459-5C0E4391DABBQ39229171-196F02C2-7FED-4A42-93DC-FA8AEC573864Q44689460-A377785C-9F5A-445F-A0C0-9D4FE4DA27F8Q47103290-D8EC773A-20D8-488F-826D-ED59D5C20ADDQ47684416-DCFF80B0-1B32-405F-A147-32EB8A5190F1Q48124146-B0DB5900-098C-42C0-97E0-663561A30F3DQ48262529-E2AC63E1-0E77-468C-A962-AF8F7E309F89Q49301622-2EA0AA68-B063-42FB-9E61-900BD3013110Q49819513-2B27576E-235D-4B5A-8A71-3395BF5F4F2BQ50216943-F5A6CE58-4A1A-49B5-81A7-8D35D76C0C0CQ50326811-AC865683-5D2A-4D21-A108-9426A70E166AQ50640303-37239ED7-8EDE-423B-ACD4-1EDFDA5CF9ACQ51193164-F1B73B5B-E2E9-4FB9-8D2B-F75BD4DB41B1Q51549829-8B150A17-ADCE-46D2-997E-82F6BB671EA9Q51684531-663BF5FE-4764-4F44-AA7A-E2DA0CED1D75
P2860
Dual loss of the SWI/SNF complex ATPases SMARCA4/BRG1 and SMARCA2/BRM is highly sensitive and specific for small cell carcinoma of the ovary, hypercalcaemic type.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Dual loss of the SWI/SNF compl ...... he ovary, hypercalcaemic type.
@ast
Dual loss of the SWI/SNF compl ...... he ovary, hypercalcaemic type.
@en
type
label
Dual loss of the SWI/SNF compl ...... he ovary, hypercalcaemic type.
@ast
Dual loss of the SWI/SNF compl ...... he ovary, hypercalcaemic type.
@en
prefLabel
Dual loss of the SWI/SNF compl ...... he ovary, hypercalcaemic type.
@ast
Dual loss of the SWI/SNF compl ...... he ovary, hypercalcaemic type.
@en
P2093
P2860
P356
P1476
Dual loss of the SWI/SNF compl ...... the ovary, hypercalcaemic type
@en
P2093
Anthony N Karnezis
Bernard E Weissman
Brigitte M Ronnett
C Blake Gilks
Christine Chow
David G Huntsman
Emanuela D'Angelo
Esther Oliva
Friedrich Kommoss
Jaime Prat
P2860
P304
P356
10.1002/PATH.4633
P577
2015-12-21T00:00:00Z